At 13:35 on May 25th, with the grand opening of the 2017 National Tuberculosis Academic Conference and the 80th Anniversary of the Founding of the Tuberculosis Branch of the Chinese Medical Association Tuberculosis Branch. The conference entered the important project release link with the theme of "Inheritance and Innovation".
This time, the Beijing Tuberculosis Diagnosis and Treatment Technology Innovation Alliance ("Innovation Alliance") and the Chinese Medical Association Tuberculosis Branch ("TB Branch") have added two new important projects. One is the "Young Eagle" project jointly initiated by the Innovation Alliance and Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical"), a member company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical"). The other is the "Multidrug-resistant Tuberculosis Medical Cooperation" project co-sponsored by Xi'an Janssen.
The "Young Eagle" project is the first major talent training project co-operated by Hongqi Pharmaceutical and Innovation Alliance and Tuberculosis Branch. The project plans to invest 400,000 yuan per year (including 300,000 for Hongqi Pharmaceutical and 100,000 for Innovation Alliance) for 5 consecutive years for young and middle-aged tuberculosis medical staff to participate in relevant academic exchanges and continuous training. The aim is to inherit and carry forward the fine tradition of the Tuberculosis Branch that has always attached importance to the training of young talents. Through this project, more young people in the field of tuberculosis are encouraged to grow faster. Improve the technical level of prevention and treatment personnel to better serve our country's tuberculosis prevention and treatment work. At the same time, more companies will be encouraged to support the training of young talents in the tuberculosis field in my country.
The signing ceremony of the project was presided over by Li Liang, the chief physician of Beijing Chest Hospital affiliated to Capital Medical University and the candidate chairman of the Chinese Medical Association Tuberculosis Branch. First of all, Professor Li Liang briefly introduced the innovation, demonstration and leading role of the Innovation Alliance in scientific research, medical technology support, and informatization since its establishment.
Afterwards, Professor Li Liang solemnly announced that the project signing ceremony has officially started. Professor Xu Shaofa, the chairman of the Innovation Alliance and former chairman of the tuberculosis branch, and Mr. Li Shaowei, general manager of the sales department of Hongqi Pharmaceutical, came to the stage to sign the contract. Accompanied by the majestic and solemn music, the "Young Eagle Project" contract was successfully officially launched, and the audience responded with warm applause. More than a thousand expert representatives attended the meeting to witness this glorious moment!
At the end of the signing ceremony, Professor Li Liang happily expressed his sincere gratitude to Hongqi Pharmaceutical for its corporate social responsibility. At the same time, he was full of confidence and good expectations for the future cooperation with Hongqi Pharmaceutical, and solemnly invited Li Shaowei, the representative of the company, to speak on stage.
In the warm applause, Li Shaowei delivered a calm and sincere speech. First of all, on behalf of the group and the company, thank the doctors who have been fighting on the front line of tuberculosis for their selfless dedication. Secondly, it was introduced that Hongqi Pharmaceutical, a member company of Fosun Pharma, has been committed to the prevention and control of tuberculosis, focusing on the research and development of high-quality drugs. Develop international cooperation. Through corporate funding and co-organization of innovation alliances, we will train medical backbones for the country. Promote domestic and international medical exchanges in the field of anti-tuberculosis, and improve the technical level of tuberculosis diagnosis and treatment.
At the same time, we hope to drive more companies to participate in the Young Eagle Project. Through joint efforts to improve the technical level of tuberculosis diagnosis and treatment, and strengthen exchanges and cooperation between enterprises and hospitals, we will definitely be able to eliminate the problem of tuberculosis.
Hongqi Pharmaceutical takes "Let humans no longer be troubled by tuberculosis" as its mission and "creating a world-class anti-tuberculosis drug company" as its vision. The company is currently undergoing upgrading and transformation to build a world-class tuberculosis drug production base. The first-line products are undergoing consistency evaluation, PQ certification, and efforts are being made to develop and introduce second-line products: PA-824, Diyimadi, PAS particles, etc.
Finally, it expressed that Fosun Pharma and its member company Hongqi Pharmaceutical will continue to support the work of the innovation alliance and contribute to the achievement of the national tuberculosis control target in the 13th Five-Year Plan as soon as possible.